- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Low-dose contraceptive patch comparable to combination oral contraceptive in safety, tolerability study
A low-dose contraceptive patch is comparable to combination oral contraceptive in a comparative study, according to phase 3 data presented at the American College of Obstetricians and Gynecologists' (ACOG) 60th Annual Clinical Meeting.
A low-dose contraceptive patch is comparable to combination oral contraceptive in a comparative study, according to phase 3 data presented at the American College of Obstetricians and Gynecologists’ (ACOG) 60th Annual Clinical Meeting.
A once-weekly, low-dose combination contraceptive patch (AG200-15, Agile) containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG) was evaluated in a diverse population of more than 1,500 women, including obese women, minorities, and new users of hormonal contraceptives. This comparative study demonstrated that AG200-15 has contraceptive efficacy comparable to that of an approved low-dose oral contraceptive comparator, as well as a similar safety and tolerability profile.
“Unlike many contraceptive clinical trials, this study was conducted in a population that reflects all US reproductive-age women,” said Andrew Kaunitz, MD, associate chair and professor of the department of obstetrics and gynecology at the University of Florida. Dr Kaunitz is the principal investigator for the AG200-15 phase 3 trial.
Two additional studies also were presented at ACOG by David F. Archer, MD, professor of obstetrics and gynecology at Eastern Virginia Medical School. The first demonstrated that the investigational patch can be worn on any of the 3 administration sites (abdomen, buttock, or upper torso), without any clinically significant differences in blood levels of the active ingredients, EE and LNG. The second study showed that the patch can be worn under various conditions, including in the whirlpool and sauna, and during vigorous exercise, without any clinically significant difference in blood levels.
The phase 3 AG200-15 data also shows greater compliance than oral contraceptives with study participants having fewer missed days of contraception with the once-weekly patch than with oral contraceptives. Data were presented from 1,328 women, of whom 998 received the patch and 330 received an oral contraceptive. Over the first 6 cycles of the study, the percentage of cycles with perfect compliance was significantly higher in the patch group than in the pill group (90.5% vs 78.8%, P<.001). Additionally, compliance with the patch improved over the 6 cycles, while compliance with the pill worsened.
“Noncompliance among contraceptive users is an ongoing challenge, as the effectiveness of a contraceptive can decrease if it is not used correctly,” Dr Kaunitz said. â
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
